ArticleBMC cancer2025
Study protocol for a single-arm phase Ib/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06844422 (Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective treatment options, contributing to its high mortality of rate. Radiotherapy has shown effect in converting PDAC from a "cold tumor" to "hot tumor”, thus enhancing its response to immunotherapy. The synergistic effect of radiotherapy and immunotherapy may further improve therapeutic efficacy. Additionally, studies have demonstrated that vascular endothelial growth factor (VEGF) inhibitors can enhance the effectiveness of anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immune-permissive TME. This study aims to investigate the efficacy and safety of Ivonescimab-a bispecific antibody against programmed cell death protein 1 and VEGF-in combined with stereotactic body radiotherapy (SBRT) and chemotherapy for treating locally advanced pancreatic cancer (LAPC).
methodsThis is a single-arm, Phase Ib/II clinical study designed to recruit 37 patients with LAPC (NCT06844422). Before enrollment, participants must undergo a comprehensive clinical evaluation, including imaging and cytological or histopathological examinations. The objective of Phase Ib was to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended Phase II dose (RP2D) of Ivonescimab. The Phase Ib component follows a dose-escalation design using a 3 + 3 methodology to deterime DLT over 4-week period, establishing the recommended Phase II dose (RP2D) of Ivonescimab. In Phase II, the study aimed to investigate the median progression-free survival (mPFS) for patients with PDAC. The Phase II portion is a single-arm study utilizing the RP2D of Ivonescimab as determined in Phase Ib. Initially, participants will receive Ivonescimab in combination with SBRT (25-50 Gy/5F) over 2 weeks, followed by up to 8–10 cycles of Ivonescimab combined with modified FOLFIRINOX (mFOLFIRINOX; oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2 and fluorouracil 2400 mg/m2). Maintenance treatment with Ivonescimab may continue based on individual tolerance, up to 12 months or until intolerable toxicity or disease progression. DISCUSSION: This trial is to assess the safety and efficacy of Ivonescimab in combination with SBRT and chemotherapy as first-line treatment for LAPC. The fingdings from this Phase Ib/II study will provide critical insights to inform future treatment selection and therapeutic planning for patients with LAPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.